BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. (BLLN) is the issuer of Class A common stock subject to a planned resale under Rule 144 by account holder David Tsao. The notice covers a proposed sale of 10,000 Class A shares through Fidelity Brokerage Services LLC, with an indicated aggregate value of $1,000,000.00 and reference to 42,644,388 shares outstanding as of August 25, 2026.
The shares are to be sold following a stock option exercise for cash scheduled for August 25, 2026. The notice also lists sales in the past three months by David Tsao and the DT 2021 Irrevocable Trust, for which Icontrust LLC acts as trustee and in which Tsao is an account stakeholder. The notice is signed by Emily Navaro as attorney-in-fact for David Tsao.
BillionToOne, Inc. (BLLN) is the issuer for a Form 144 notice filed on behalf of officer John R. Ten Bosch. The notice covers a proposed sale of 1,417 Class A shares to be sold through Fidelity Brokerage Services LLC. It also reports prior open-market sales of Class A shares by John R. Ten Bosch during June–August 2026, including 2,832 shares on June 15, 1,416 shares on June 29, 4,251 shares on July 13, and 1,417 shares on August 10, 2026. The securities described include Class A shares originally acquired on December 30, 2021 as pre-IPO shares received as compensation.
BillionToOne, Inc. senior vice president of laboratory operations John Roderick ten Bosch reported selling 1,417 shares of Class A Common Stock on August 10, 2026 at $92.86 per share. After this sale, he held 27,884 shares directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. director and Chief Technology Officer David Tsao exercised stock options for 10,000 shares of Class A Common Stock at $2.80 per share on August 10, 2026, then sold 10,000 shares of Class A Common Stock at $92.86 per share. Following the option exercise, he held 590,000 stock options that are fully vested and exercisable, expiring June 7, 2031. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
John R. Ten Bosch filed a notice to sell 1,417 Class A shares of BLLN, held at Fidelity Brokerage Services, with an indicated value of $131,582.62, on NASDAQ by August 10, 2026. These shares are described as Pre IPO Shares originally received as compensation.
Over the prior three months, Ten Bosch reported Class A sales of 2,832 shares for $287,363.04 on June 15, 2026, 1,416 shares for $169,920.00 on June 29, 2026, and 4,251 shares for $533,330.46 on July 13, 2026.
BLLN has a notice of proposed sale of restricted securities. An affiliated holder plans to sell 3,500 Class A shares on or after August 10, 2026 through Fidelity Brokerage Services LLC on NASDAQ. The disclosure also lists prior Class A share sales by David Tsao and the Dt 2021 Irrevocable Trust in June and July 2026, including multiple transactions of 20,000 and 3,500 shares with multi-hundred-thousand-dollar proceeds.
BillionToOne (symbol BLLN) has a Form 144/A filing indicating that insider David Tsao plans to sell 10,000 Class A shares through Fidelity Brokerage Services on 08/10/2026, following a stock option exercise. The planned sale reflects an aggregate market value of $928,600.00 on NASDAQ.
Over the prior three months, reported sales of Class A shares included 20,000 shares for $2,045,326.00 and 20,000 shares for $2,497,697.77 by David Tsao, plus 3,500 shares for $355,145.00 and 3,500 shares for $439,110.00 by the DT 2021 Irrevocable Trust.
A shareholder of BLLN, identified as David Tsao, has filed a notice of intent to sell 10,000 Class A shares through Fidelity Brokerage Services on NASDAQ, with an indicated value of $928,600.00 as of August 10, 2026.
The filing also reports prior sales of 20,000 Class A shares for $2,045,326.00 on June 15, 2026 and another 20,000 shares for $2,497,698.00 on July 13, 2026. The upcoming sale is associated with a stock option exercise to be settled in cash.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan exercised stock options to acquire 15,539 shares of Class A Common Stock at $2.80 per share, then sold 15,539 shares at a weighted average of $150.0323 per share. The options were fully vested and exercisable, leaving 526,961 stock options outstanding. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan reported multiple equity transactions in Class A Common Stock. On August 3, 2026 he exercised stock options to acquire 32,500 shares at $2.80 per share from fully vested awards expiring 2031-06-07, and reported sales totaling 45,000 shares in numerous trades at weighted average prices between $132.500 and $139.500 per share, including shares held by his spouse. All transactions were effected under a Rule 10b5-1 trading plan adopted March 6, 2026.